An antigen-strengthened dye-modified fully-human-nanobody-based immunoprobe for second near infrared bioimaging of metastatic tumors. (August 2022)

• Record Type: Journal Article
• Authors: Shi, Yibing; Wu, Huifang; Hu, Weiqiang; Jin, Yujia; Kong, Mengya; Wang, Yulu; Chen, Binfan; Li, Quanxiao; Huang, Keke; Yang, Zhenlin; Li, Fuyou; Wu, Yanling; Ying, Tianlei
• Is Part Of: Biomaterials. Volume 287(2022)
• Publication Date: 2022-08
• Subjects: Second near infrared -- Fully human nanobody -- Dye -- Immunoprobe -- Metastatic tumor -- Bioimaging; Biomedical materials -- Periodicals; Biocompatible Materials -- Periodicals; Biomatériaux -- Périodiques; 610.28
• DOI: 10.1016/j.biomaterials.2022.121637
• Languages: English
• ISSNs: 0142-9612

Abstract

Abstract: Conventional immunoprobes have absorption capabilities across the visible to near infrared (NIR-I, 650–900 nm) region. Recently, second near infrared (NIR-II, 1000–1700 nm) window have gained much attention due to their deeper penetration depth and improved visualization. Here, we describe the design and synthesis of a fully human nanobody-based fluorescent immunoprobe (ICGM-n501) for NIR-II bioimaging with strengthened fluorescent emission by antigen for the first time. By site-directed conjugation of an FDA-approved dye analogue, indocyanine green decorated with maleimide (ICGM), into a tumor-specific n501, ICGM-n501 provides real-time monitoring of abdominal transportation pathway of antibody-based bioagents with high resolution (0.21 mm), presents better accuracy and lower dosage (0.21 μmol kg −1 ) in bioimaging of peritoneal metastatic tumors than bioluminescence agent D-luciferin. In this work, ICGM-n501 demonstrates its potential in clinical surgery guidance, provide an expanded category of available NIR-II fluorophores and a template for next-generation immunoassay bioagents.